<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CARBOPLATIN- carboplatin injection </strong><br>Mylan Institutional LLC <br></p></div>
<h1>Carboplatin Injection<br>Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID125"></a><a name="section-1"></a><p></p>
<p class="First"><a name="ID126"></a><span class="Bold">                                                                      WARNING</span></p>
<p>Carboplatin injection should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.</p>
<p>Bone marrow suppression is dose related and may be severe, resulting in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> may be cumulative and may require transfusion support. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> is another frequent drug-related side effect.</p>
<p>Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID127"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="ID128"></a>Carboplatin Injection is for intravenous administration. Each mL contains equivalent to 10 mg of carboplatin in Water for Injection. No other preservatives or additives are present. Carboplatin injection is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin. Carboplatin is a platinum coordination compound. The chemical name for carboplatin is platinum, diammine [1,1-cyclobutanedicarboxylato(2-)-<span class="Italics">O,O<span class="Sup">’</span></span>]-,(<span class="Italics">SP</span>-4-2), and carboplatin has the following structural formula:</p>
<div class="Figure"><img alt="image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806736d3-215a-4df5-8187-97f2161e5a53&amp;name=carbo-inj-novaplus-mylan-figure-01.jpg"></div>
<p><a name="ID130"></a>Carboplatin is a crystalline powder with the molecular formula of C<span class="Sub">6</span>H<span class="Sub">12</span>N<span class="Sub">2</span>O<span class="Sub">4</span>Pt and a molecular weight of 371.25. It is soluble in water at a rate of approximately 14 mg/mL, and the pH of a 1% solution is 5-7.  It is sparingly soluble in water, very slightly soluble in acetone and in alcohol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID131"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="ID132"></a>Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates. </p>
<p>In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 mg/m<span class="Sup">2</span> to 500 mg/m<span class="Sup">2</span> of carboplatin. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (n=6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (n=6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The C<span class="Sub">max</span> values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 mg/m<span class="Sup">2</span> to 500 mg/m<span class="Sup">2</span>).</p>
<p>Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days. </p>
<p>The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs.</p>
<p>In patients with creatinine clearances below 60 mL/min the total body and renal clearances of carboplatin decrease as the creatinine clearance decreases. Carboplatin dosages should therefore, be reduced in these patients (see <span class="Bold"><a href="#ID196">DOSAGE AND ADMINISTRATION</a> </span>).</p>
<p>The primary determinant of carboplatin clearance is glomerular filtration rate (GFR) and this parameter of renal function is often decreased in elderly patients. Dosing formulas incorporating estimates of GFR (see <span class="Bold"><a href="#ID196">DOSAGE AND ADMINISTRATION</a> </span>) to provide predictable carboplatin plasma AUCs should be used in elderly patients to minimize the risk of toxicity.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID133"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<div class="Section">
<a name="ID134"></a><a name="section-3.1"></a><p></p>
<h2>Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer</h2>
<p class="First"><a name="ID135"></a>In two prospectively randomized, controlled studies conducted by the National Cancer Institute of Canada, Clinical Trials Group (NCIC) and the Southwest Oncology Group (SWOG), 789 chemotherapy naive patients with advanced ovarian cancer were treated with carboplatin or cisplatin, both in combination with cyclophosphamide every 28 days for 6 courses before surgical reevaluation. The following results were obtained from both studies:</p>
<a name="ID136"></a><table width="100%">
<caption><span>Comparative Efficacy</span></caption>
<col width="50%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top">
<span class="Bold">Overview </span><span class="Bold">of </span><span class="Bold">Pivotal </span><span class="Bold">Trials</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">NCIC</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">SWOG</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Number of patients randomized<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">447<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">342<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Median age (years)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">60<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">62<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Dose of cisplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">75 mg/m<span class="Sup">2</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">100 mg/m<span class="Sup">2</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Dose of carboplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">300 mg/m<span class="Sup">2</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">300 mg/m<span class="Sup">2</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Dose of cyclophosphamide<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">600 mg/m<span class="Sup">2</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">600 mg/m<span class="Sup">2</span><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Residual tumor &lt;2 cm (number of patients)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">39% (174/447)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">14% (49/342)<br>
</td>
</tr>
</tbody>
</table>
<a name="ID137"></a><table width="100%">
<caption><span>Clinical Response in Measurable Disease Patients</span></caption>
<col width="50%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">NCIC</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">SWOG</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin  (number of patients)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">60% (48/80)<span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="middle">58% (48/83)<span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin  (number of patients)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">58% (49/85)<span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="middle">43% (33/76)<span class="Bold"><br></span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">95% CI of difference <br>(Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-13.9%, 18.6%)<span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="middle">(-2.3%, 31.1%)<br>
</td>
</tr>
</tbody>
</table>
<a name="ID138"></a><table width="101%">
<caption><span>Pathologic Complete Response<span class="Sup">*</span></span></caption>
<col width="54%">
<col width="24%">
<col width="23%">
<tfoot>
<tr class="First"><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span>114 Carboplatin and 109 Cisplatin patients did not undergo second look surgery in NCIC study <br></p></td></tr>
<tr class="Last"><td align="left" colspan="3"><p class="First Footnote">90 Carboplatin and 106 Cisplatin patients did not undergo second look surgery in SWOG study<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">NCIC</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">SWOG</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin  (number of patients)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">11% (24/224)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">10% (17/171)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin  (number of patients)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">15% (33/223)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">10% (17/171)<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">95% CI of difference (Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-10.7%, 2.5%)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-6.9%, 6.9%)<br>
</td>
</tr>
</tbody>
</table>
<a name="ID139"></a><table width="100%">
<caption><span>Progression-Free Survival (PFS)</span></caption>
<col width="50%">
<col width="25%">
<col width="25%">
<tfoot>
<tr class="First"><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span>Kaplan-Meier Estimates<br></p></td></tr>
<tr><td align="left" colspan="3"><p class="First Footnote">Unrelated <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurring in the absence of progression were counted as events (progression) in this analysis.<br></p></td></tr>
<tr class="Last"><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span><span class="Sup">*</span>Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis.<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">NCIC</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">SWOG</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<span class="Bold">Median</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">59 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">49 weeks<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">61 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">47 weeks<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" colspan="1" valign="top">
<span class="Bold">2</span><span class="Bold">-</span><span class="Bold">year </span><span class="Bold">PFS</span><span class="Bold"><span class="Sup">*</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">31%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">21%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">31%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">21%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">95% CI of difference<br>(Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-9.3, 8.7)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-9.0, 9.4)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<span class="Bold">3</span><span class="Bold">-</span><span class="Bold">year </span><span class="Bold">PFS</span><span class="Bold"><span class="Sup">*</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">19%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">8%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">23%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">14%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">95% CI of difference <br>(Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-11.5, 4.5)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-14.1, 0.3)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Hazard </span><span class="Bold">Ratio</span><span class="Bold"><span class="Sup">*</span><span class="Sup">*</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">1.10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">1.02<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">95% CI (Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(0.89, 1.35)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(0.81, 1.29)<br>
</td>
</tr>
</tbody>
</table>
<a name="ID140"></a><table width="100%">
<caption><span>Survival</span></caption>
<col width="56%">
<col width="22%">
<col width="22%">
<tfoot>
<tr class="First"><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span>Kaplan-Meier Estimates<br></p></td></tr>
<tr class="Last"><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span><span class="Sup">*</span>Analysis adjusted for factors found to be of prognostic significance were consistent with unadjusted analysis. <br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">NCIC</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">SWOG</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="middle">
<span class="Bold">Median</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="middle"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">110 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">86 weeks<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">99 weeks<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">79 weeks<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<span class="Bold">2</span><span class="Bold">-</span><span class="Bold">year </span><span class="Bold">Survival</span><span class="Bold"><span class="Sup">*</span></span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">51.9%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">40.2%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">48.4%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">39.0%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">95% CI of difference  (Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-6.2, 13.2)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-9.8, 12.2)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<span class="Bold">3</span><span class="Bold">-</span><span class="Bold">year </span><span class="Bold">Survival</span><span class="Bold"><span class="Sup">*</span></span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Carboplatin <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">34.6%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">18.3%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Cisplatin <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">33.1%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">24.9%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">95% CI of difference<br>(Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-7.7, 10.7)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(-15.9, 2.7)<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Hazard </span><span class="Bold">Ratio</span><span class="Bold"><span class="Sup">*</span><span class="Sup">*</span></span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">0.98<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">1.01<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">95% CI (Carboplatin-Cisplatin)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(0.78, 1.23)<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">(0.78, 1.30)<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID141"></a><a name="section-3.2"></a><p></p>
<h2>Comparative Toxicity</h2>
<p class="First"><a name="ID142"></a>The pattern of toxicity exerted by the carboplatin-containing regimen was significantly different from that of the cisplatin-containing combinations. Differences between the two studies may be explained by different cisplatin dosages and by different supportive care.</p>
<p>The carboplatin-containing regimen induced significantly more <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and, in one study, significantly more <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and more need for transfusional support. The cisplatin-containing regimen produced significantly more <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> in one study. However, no significant differences occurred in incidences of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and hemorrhagic episodes. </p>
<p>Non-hematologic toxicities (<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span>, renal toxicity, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>) were significantly more frequent in the cisplatin-containing arms.</p>
<a name="ID143"></a><table width="100%">
<caption><span>ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER NCIC STUDY</span></caption>
<col width="32%">
<col width="22%">
<col width="16%">
<col width="15%">
<col width="15%">
<tfoot>
<tr class="First"><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">*</span> Values are in percent of evaluable patients.<br></p></td></tr>
<tr><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">*</span><span class="Sup">*</span> ns=not significant, p&gt;0.05.<br></p></td></tr>
<tr class="Last"><td align="left" colspan="5"><p class="First Footnote">+ May have been affected by cyclophosphamide dosage delivered.<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Carboplatin </span><span class="Bold">Arm </span><span class="Bold">Percent</span><span class="Bold"><span class="Sup">*</span></span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Cisplatin </span><span class="Bold">Arm</span><span class="Bold"><br></span><span class="Bold">Percent</span><span class="Bold"><span class="Sup">*</span></span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">P</span><span class="Bold">-</span><span class="Bold">Values</span><span class="Bold"><span class="Sup">*</span><span class="Sup">*</span></span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Bone </span><span class="Bold">Marrow</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Thrombocytopenia <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 100,000/mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">70<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">29<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0. 001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 50,000 /mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">41<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;2000 cells/mm<span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">97<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">96<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;1000 cells/mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">81<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">79<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;4000 cells/mm<span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">98<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">97<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;2000 cells/mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">68<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">52<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Anemia                 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 11 g/dL<br>&lt; 8 g/dL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">91<br>18<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">91<br>12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Infections <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">14<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Bleeding <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Transfusions <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">42<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">31<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.018<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Gastrointestinal</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Nausea and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">93<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">98<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.010<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">84<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">97<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Other GI side effects <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">62<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.013<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Neurologic</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Peripheral neuropathies<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">42<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top"><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">33<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Other sensory side effects<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">Central <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">28<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.009<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="justify" valign="top">
<span class="Bold">Renal</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Serum creatinine elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.006<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Blood urea elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">31<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Hepatic</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Bilirubin elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">SGOT elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Alkaline phosphatase elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Electrolytes </span><span class="Bold">loss</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle">Sodium<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">20<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">0.005<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Potassium <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">22<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Calcium <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Magnesium <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">63<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">88<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Other </span><span class="Bold">side </span><span class="Bold">effects</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Pain <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">36<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">37<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Asthenia <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">33<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Cardiovascular <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Respiratory <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Allergic <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Genitourinary <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Alopecia +<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">50<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">62<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.017<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Mucositis <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
</tbody>
</table>
<a name="ID144"></a><table width="100%">
<caption><span>ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER SWOG STUDY</span></caption>
<col width="33%">
<col width="20%">
<col width="17%">
<col width="15%">
<col width="15%">
<tfoot>
<tr class="First"><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">*</span> Values are in percent of evaluable patients.<br></p></td></tr>
<tr><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">*</span><span class="Sup">*</span> ns=not significant, p &gt;0.05.<br></p></td></tr>
<tr class="Last"><td align="left" colspan="5"><p class="First Footnote">+ May have been affected by cyclophosphamide dosage delivered.<br></p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Carboplatin </span><span class="Bold">Arm </span><span class="Bold">Percent</span><span class="Bold"><span class="Sup">*</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Cisplatin </span><span class="Bold">Arm</span><span class="Bold"><br></span><span class="Bold">Percent</span><span class="Bold"><span class="Sup">*</span></span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">P</span><span class="Bold">-</span><span class="Bold">Values</span><span class="Bold"><span class="Sup">*</span><span class="Sup">*</span></span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Bone </span><span class="Bold">Marrow</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><span class="Bold"><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Thrombocytopenia <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 100,000/mm<span class="Sup">3</span> <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">59<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">35<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 50,000 /mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">22<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.006<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Neutropenia           <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;2000 cells/mm<span class="Sup">3</span>                                      <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">95<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">97<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;1000 cells/mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">84<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">78<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Leukopenia           <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;4000 cells/mm<span class="Sup">3</span>                             <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">97<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">97<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;2000 cells/mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">76<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">67<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Anemia                 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 11 g/dL                              <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">88<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">87<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 8 g/dL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">24<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Infections <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">18<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Bleeding <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Transfusions <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">25<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">33<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Gastrointestinal</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Nausea and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">94<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">96<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">82<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">91<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.007<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Other GI side effects <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">40<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">48<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Neurologic</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Peripheral neuropathies <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">28<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Ototoxicity <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Other sensory side effects <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Central neurotoxicity <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">23<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">29<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Renal</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Serum creatinine elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">38<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Blood urea elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Hepatic</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Bilirubin elevations<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">SGOT elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">23<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Alkaline phosphatase elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">29<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Electrolytes </span><span class="Bold">loss</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Sodium<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Potassium <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Calcium <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">-<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Magnesium <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">58<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">77<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">&lt;0.001<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Other </span><span class="Bold">side </span><span class="Bold">effects</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Pain <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">54<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">52<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Asthenia <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">43<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">46<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Cardiovascular <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">23<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">30<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Respiratory <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Allergic <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Genitourinary <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Alopecia +<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">43<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">57<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.009<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Mucositis <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">ns<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID145"></a><a name="section-3.3"></a><p></p>
<h2>Use as a Single Agent for Secondary Treatment of Advanced Ovarian Cancer</h2>
<p class="First"><a name="ID146"></a>In two prospective, randomized controlled studies in patients with advanced ovarian cancer previously treated with chemotherapy, carboplatin achieved 6 clinical complete responses in 47 patients. The duration of these responses ranged from 45 to 71 +<span class="Sup"></span>weeks.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID245"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS</h1>
<div class="Section">
<a name="ID246"></a><a name="section-4.1"></a><p></p>
<h2>Initial Treatment of Advanced Ovarian Carcinoma</h2>
<p class="First"><a name="ID247"></a>Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see <span class="Bold"><a href="#ID133">CLINICAL STUDIES</a> </span>). </p>
<p>There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor &lt;2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup.</p>
</div>
<div class="Section">
<a name="ID248"></a><a name="section-4.2"></a><p></p>
<h2>Secondary Treatment of Advanced Ovarian Carcinoma</h2>
<p class="First"><a name="ID249"></a>Carboplatin is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin.</p>
<p>Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID153"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="ID154"></a>Carboplatin injection is contraindicated in patients with a history of severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to cisplatin or other platinum-containing compounds.</p>
<p>Carboplatin should not be employed in patients with severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> or significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID155"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="ID156"></a>Bone marrow suppression (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during carboplatin treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single-agent carboplatin. In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered.</p>
<p>Since <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> is cumulative, transfusions may be needed during treatment with carboplatin, particularly in patients receiving prolonged therapy.</p>
<p>Bone marrow suppression is increased in patients who have received prior therapy, especially regimens including cisplatin. Marrow suppression is also increased in patients with impaired kidney function. Initial carboplatin dosages in these patients should be appropriately reduced (see <span class="Bold"><a href="#ID196">DOSAGE AND ADMINISTRATION</a></span>) and blood counts should be carefully monitored between courses. The use of carboplatin in combination with other bone marrow suppressing therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects.</p>
<p>Carboplatin has limited nephrotoxic potential, but concomitant treatment with aminoglycosides has resulted in increased renal and/or audiologic toxicity, and caution must be exercised when a patient receives both drugs. Clinically significant <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other ototoxic agents.</p>
<p>Carboplatin can induce <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, which can be more severe in patients previously receiving emetogenic therapy. The incidence and intensity of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> have been reduced by using premedication with antiemetics. Although no conclusive efficacy data exist with the following schedules of carboplatin, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over 5 consecutive daily pulse doses has resulted in reduced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</p>
<p>Although peripheral <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin. Pre-existing cisplatin-induced <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> does not worsen in about 70% of the patients receiving carboplatin as secondary treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Loss of vision</span>, which can be complete for light and colors, has been reported after the use of carboplatin with doses higher than those recommended in the package insert. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses. </p>
<p>As in the case of other platinum-coordination compounds, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to carboplatin have been reported. These may occur within minutes of administration and should be managed with appropriate supportive therapy. There is increased risk of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> in patients previously exposed to platinum therapy. (See <span class="Bold"><a href="#ID153">CONTRAINDICATIONS </a></span>and   <span class="Bold"><a href="#ID188">ADVERSE REACTIONS: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>.</a></span>)  </p>
<p>High dosages of carboplatin (more than 4 times the recommended dose) have resulted in severe abnormalities of liver function tests. </p>
<p>Carboplatin injection may cause fetal harm when administered to a pregnant woman. Carboplatin has been shown to be embryotoxic and teratogenic in rats. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID157"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section">
<a name="ID158"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><a name="ID159"></a><span class="Bold">Needles  or  intravenous  administration  sets  containing  aluminum  parts  that  may come  in  contact  with Carboplatin injection should  not  be  used  for  the  preparation  or  administration  of  the  drug.  Aluminum can react with carboplatin causing precipitate formation and loss of potency.</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID160"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="ID161"></a>The renal effects of nephrotoxic compounds may be potentiated by carboplatin.</p>
</div>
<div class="Section">
<a name="ID162"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="ID163"></a>The carcinogenic potential of carboplatin has not been studied, but compounds with similar mechanisms of action and mutagenicity profiles have been reported to be carcinogenic. Carboplatin has been shown to be mutagenic both <span class="Italics">in vitro </span>and <span class="Italics">in vivo. </span>It has also been shown to be embryotoxic and teratogenic in rats receiving the drug during organogenesis. Secondary malignancies have been reported in association with multi-drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID164"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><a name="ID165"></a><span class="Bold">Pregnancy Category D</span></p>
<p>See <span class="Bold"><a href="#ID155">WARNINGS</a></span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID166"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="ID167"></a>It is not known whether carboplatin is excreted in human milk. Because there is a possibility of toxicity in nursing infants secondary to carboplatin treatment of the mother, it is recommended that breast feeding be discontinued if the mother is treated with carboplatin injection.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID168"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="ID169"></a>Safety and effectiveness in pediatric patients have not been established (see <span class="Bold"><a href="#ID155">WARNINGS </a>"</span>audiologic toxicity").</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID170"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><a name="ID171"></a>Of the 789 patients in initial treatment combination therapy studies (NCIC and SWOG), 395 patients were treated with carboplatin in combination with cyclophosphamide. Of these, 141 were over 65 years of age and 22 were 75 years or older. In these trials, age was not a prognostic factor for survival. In terms of safety, elderly patients treated with carboplatin were more likely to develop severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> than younger patients. In a combined database of 1,942 patients (414 were ≥65 years of age) that received single-agent carboplatin for different tumor types, a similar incidence of adverse events was seen in patients 65 years and older and in patients less than 65. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Because renal function is often decreased in the elderly, renal function should be considered in the selection of carboplatin dosage (see <span class="Bold"><a href="#ID196">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID172"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="ID173"></a>For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see <span class="Bold"><a href="#ID133">CLINICAL STUDIES:</a>: </span><span class="Bold">Comparative Toxicity</span>.</p>
<a name="ID234"></a><table width="100%">
<caption><span>ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER</span></caption>
<col width="36%">
<col width="21%">
<col width="22%">
<col width="21%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top"> <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">First </span><span class="Bold">Line</span><span class="Bold"><br></span><span class="Bold">Combination</span><span class="Bold"><br></span><span class="Bold">Therapy</span><span class="Bold"><span class="Sup">*</span><span class="Sup"> </span></span><span class="Bold">Percent</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Second </span><span class="Bold">Line</span><span class="Bold"><br></span><span class="Bold">Single </span><span class="Bold">Agent </span><span class="Bold">Therapy</span><span class="Bold"><span class="Sup">*</span><span class="Sup">*</span><span class="Sup"> </span></span><span class="Bold">Percent</span><br>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Bone </span><span class="Bold">Marrow</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><br></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold"><br></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Thrombocytopenia <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;100,000/mm<span class="Sup">3</span>                           <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">66<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">62<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 50,000 /mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">33<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">35<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Neutropenia           <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;2000 cells/mm<span class="Sup">3</span>                              <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">96<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">67<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;1000 cells/mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">82<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Leukopenia           <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;4000 cells/mm<span class="Sup">3</span>                              <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">97<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">85<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt;2000 cells/mm<span class="Sup">3</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">71<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">26<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Anemia                 <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 11 g/dL                              <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">90<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">90<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">&lt; 8 g/dL<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">14<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Infections <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Transfusions <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">35<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">44<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Gastrointestinal</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Nausea and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">93<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">92<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">83<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">81<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Other GI side effects <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">46<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">21<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Neurologic</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Peripheral neuropathies <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">15<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Ototoxicity <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Other sensory side effects <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Central neurotoxicity <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">26<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Renal</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Serum creatinine elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Blood urea elevations <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">22<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Hepatic</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Bilirubin elevations<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">SGOT elevations<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">20<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Alkaline phosphatase elevations<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">29<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">37<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Electrolytes </span><span class="Bold">loss</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Sodium<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">47<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Potassium<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">28<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Calcium<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">31<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Magnesium<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">61<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">43<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Other </span><span class="Bold">side </span><span class="Bold">effects</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">44<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">23<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">41<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Cardiovascular<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">19<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Respiratory<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Allergic<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Genitourinary<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">10<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">49<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucositis</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">8<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID235"></a><span class="Bold">*Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: </span>Data are based on the experience of 393 patients with ovarian cancer (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see <span class="Bold"><a href="#ID133">CLINICAL STUDIES</a>).</span></p>
<p><a name="ID236"></a>Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table.</p>
<p><span class="Bold">**Single Agent Use for the Secondary Treatment of Ovarian Cancer: </span>Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single-agent carboplatin</p>
<p><a name="ID175"></a>In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single-agent therapy.</p>
<div class="Section">
<a name="ID176"></a><a name="section-8.1"></a><p></p>
<h2>Hematologic Toxicity</h2>
<p class="First"><a name="ID177"></a>Bone marrow suppression is the dose-limiting toxicity of carboplatin. <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> with platelet counts below 50,000/mm<span class="Sup">3</span> occurs in 25% of the patients (35% of pretreated ovarian cancer patients); <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> with granulocyte counts below 1,000/mm<span class="Sup">3</span> occurs in 16% of the patients (21% of pretreated ovarian cancer patients); <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> with WBC counts below 2,000/mm<span class="Sup">3</span> occurs in 15% of the patients (26% of pretreated ovarian cancer patients). The nadir usually occurs about day 21 in patients receiving single-agent therapy. By day 28, 90% of patients have platelet counts above 100,000/mm<span class="Sup">3</span>; 74% have neutrophil counts above 2,000/mm<span class="Sup">3</span>; 67% have leukocyte counts above 4,000/mm<span class="Sup">3</span>.</p>
<p>Marrow suppression is usually more severe in patients with impaired kidney function. Patients with poor performance status have also experienced a higher incidence of severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>The hematologic effects, although usually reversible, have resulted in infectious or hemorrhagic complications in 5% of the patients treated with carboplatin, with drug-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> occurring in less than 1% of the patients. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> has also been reported in patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> with hemoglobin less than 11 g/dL has been observed in 71% of the patients who started therapy with a baseline above that value. The incidence of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> increases with increasing exposure to carboplatin. Transfusions have been administered to 26% of the patients treated with carboplatin (44% of previously treated ovarian cancer patients). </p>
<p><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Bone marrow depression</span> may be more severe when carboplatin is combined with other bone marrow suppressing drugs or with radiotherapy.</p>
</div>
<div class="Section">
<a name="ID178"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></h2>
<p class="First"><a name="ID179"></a><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> occurs in 65% of the patients (81% of previously treated ovarian cancer patients) and in about one-third of these patients it is severe. Carboplatin, as a single agent or in combination, is significantly less emetogenic than cisplatin; however, patients previously treated with emetogenic agents, especially cisplatin, appear to be more prone to <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> alone occurs in an additional 10 to 15% of patients. Both <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> usually cease within 24 hours of treatment and are often responsive to antiemetic measures. Although no conclusive efficacy data exist with the following schedules, prolonged administration of carboplatin, either by continuous 24-hour infusion or by daily pulse doses given for 5 consecutive days, was associated with less severe <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> than the single-dose intermittent schedule. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> was increased when carboplatin was used in combination with other emetogenic compounds. Other gastrointestinal effects observed frequently were <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, in 17% of the patients; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, in 6%; and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, also in 6%.</p>
</div>
<div class="Section">
<a name="ID180"></a><a name="section-8.3"></a><p></p>
<h2>Neurologic Toxicity</h2>
<p class="First"><a name="ID181"></a>Peripheral neuropathies have been observed in 4% of the patients receiving carboplatin (6% of pretreated ovarian cancer patients) with mild <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> occurring most frequently. Carboplatin therapy produces significantly fewer and less severe neurologic side effects than does therapy with cisplatin. However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased risk (10%) for peripheral neuropathies. In 70% of the patients with pre-existing cisplatin-induced peripheral <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>, there was no worsening of symptoms during therapy with carboplatin. Clinical <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> and other sensory abnormalities such as <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> and change in taste have been reported in only 1% of the patients. Central nervous system symptoms have been reported in 5% of the patients and appear to be most often related to the use of antiemetics.</p>
<p>Although the overall incidence of peripheral neurologic side effects induced by carboplatin is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span>.</p>
</div>
<div class="Section">
<a name="ID182"></a><a name="section-8.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></h2>
<p class="First"><a name="ID183"></a>Development of abnormal renal function test results is uncommon, despite the fact that carboplatin, unlike cisplatin, has usually been administered without high-volume fluid hydration and/or forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. The incidences of abnormal renal function tests reported are 6% for serum creatinine and 14% for blood urea nitrogen (10% and 22%, respectively, in pretreated ovarian cancer patients). Most of these reported abnormalities have been mild and about one-half of them were reversible.</p>
<p>Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving carboplatin, and it appears to be the most useful test for correlating drug clearance and bone marrow suppression. Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during carboplatin therapy.</p>
</div>
<div class="Section">
<a name="ID184"></a><a name="section-8.5"></a><p></p>
<h2>Hepatic Toxicity</h2>
<p class="First"><a name="ID185"></a>The incidences of <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> in patients with normal baseline values were reported as follows: total bilirubin, 5%; <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, 15%; and alkaline phosphatase, 24%; (5%, 19%, and 37%, respectively, in pretreated ovarian cancer patients). These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of metastatic tumor in the liver may complicate the assessment in many patients. In a limited series of patients receiving very high dosages of carboplatin and autologous bone marrow transplantation, severe abnormalities of liver function tests were reported.</p>
</div>
<div class="Section">
<a name="ID186"></a><a name="section-8.6"></a><p></p>
<h2>Electrolyte Changes</h2>
<p class="First"><a name="ID187"></a>The incidences of abnormally decreased serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%; calcium, 22%; and magnesium, 29%; (47%, 28%, 31%, and 43%, respectively, in pretreated ovarian cancer patients). Electrolyte supplementation was not routinely administered concomitantly with carboplatin, and these electrolyte abnormalities were rarely associated with symptoms.</p>
</div>
<div class="Section">
<a name="ID188"></a><a name="section-8.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First"><a name="ID189"></a><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to carboplatin has been reported in 2% of the patients. These <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been similar in nature and severity to those reported with other platinum-containing compounds, i.e, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and rarely <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported as part of postmarketing surveillance (see <span class="Bold"><a href="#ID155">WARNINGS</a></span>). These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy.</p>
</div>
<div class="Section">
<a name="ID190"></a><a name="section-8.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span></h2>
<p class="First"><a name="ID191"></a><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>, including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, have been reported during postmarketing surveillance. <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span> associated with <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> has also been reported.</p>
</div>
<div class="Section">
<a name="ID192"></a><a name="section-8.9"></a><p></p>
<h2>Other Events</h2>
<p class="First"><a name="ID193"></a><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> were the most frequently reported miscellaneous adverse effects; their relationship to the tumor and to <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was likely. <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> was reported (3%). Cardiovascular,   respiratory, genitourinary, and mucosal side effects have occurred in 6% or less of the patients. Cardiovascular events (<span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>) were fatal in less than 1% of the patients and did not appear to be related to chemotherapy. Cancer-associated <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> has been reported rarely.</p>
<p><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> have been reported as part of post marketing surveillance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID194"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="ID195"></a>There is no known antidote for Carboplatin injection overdosage. The anticipated complications of overdosage would be secondary to bone marrow suppression and/or hepatic toxicity.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID196"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="ID197"></a><span class="Bold">NOTE: Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin.</span></p>
<div class="Section">
<a name="ID198"></a><a name="section-10.1"></a><p></p>
<h2>Single-Agent Therapy</h2>
<p class="First"><a name="ID199"></a>Carboplatin injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m<span class="Sup">2</span> IV on day 1 every 4 weeks (alternatively see <span class="Bold"><a href="#ID210">Formula  Dosing</a></span>). In general, however, single intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.</p>
</div>
<div class="Section">
<a name="ID200"></a><a name="section-10.2"></a><p></p>
<h2>Combination Therapy with Cyclophosphamide</h2>
<p class="First"><a name="ID201"></a>In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: </p>
<p>Carboplatin―300 mg/m<span class="Sup">2</span> IV on day 1 every 4 weeks for 6 cycles (alternatively see <span class="Bold"><a href="#ID210">Formula Dosing</a></span>).</p>
<p>Cyclophosphamide―600 mg/m<span class="Sup">2</span> IV on day 1 every 4 weeks for 6 cycles. For directions regarding the use and administration of cyclophosphamide please refer to its package insert. (See <span class="Bold"><a href="#ID133">CLINICAL STUDIES.</a></span>)</p>
<p>Intermittent courses of carboplatin in combination with cyclophosphamide should not be repeated until the neutrophil count is at least 2,000 and the platelet count is at least 100,000.</p>
</div>
<div class="Section">
<a name="ID202"></a><a name="section-10.3"></a><p></p>
<h2>Dose Adjustment Recommendations</h2>
<p class="First"><a name="ID203"></a>Pretreatment platelet count and performance status are important prognostic factors for severity of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> in previously treated patients.</p>
<p>The suggested dose adjustments for single agent or combination therapy shown in the table below are modified from controlled trials in previously treated and untreated patients with ovarian carcinoma. Blood counts were done weekly, and the recommendations are based on the lowest post-treatment platelet or neutrophil value.</p>
<a name="ID204"></a><table width="101%">
<col width="22%">
<col width="25%">
<col width="54%">
<tfoot><tr class="First Last"><td align="left" colspan="3"><p class="First Footnote"><span class="Sup">*</span>Percentages apply to Carboplatin Injection as a single agent or to both carboplatin and cyclophosphamide in combination. In the controlled studies, dosages were also adjusted at a lower level (50% to 60%) for severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. Escalations above 125% were not recommended for these studies.<br></p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Platelets </span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<span class="Bold">Adjusted </span><span class="Bold">Dose</span><span class="Bold"><span class="Sup">*</span>(</span><span class="Bold">From </span><span class="Bold">Prior </span><span class="Bold">Course</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">&gt;100,000<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">&gt;2,000<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">125%<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">50 - 100,000<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">500 – 2,000<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">No Adjustment<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">&lt;50,000<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">&lt;500<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">75%<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID205"></a>Carboplatin is usually administered by an infusion lasting 15 minutes or longer. No pre- or post-treatment hydration or forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is required.</p>
</div>
<div class="Section">
<a name="ID206"></a><a name="section-10.4"></a><p></p>
<h2>Patients with Impaired Kidney Function</h2>
<p class="First"><a name="ID207"></a>Patients with creatinine clearance values below 60 mL/min are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single-agent carboplatin therapy, the incidence of severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> has been about 25% when the dosage modifications in the table below have been used. </p>
<a name="ID208"></a><table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Baseline  </span><span class="Bold">Creatinine </span><span class="Bold">Clearance</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Recommended </span><span class="Bold">Dose </span><span class="Bold">on </span><span class="Bold">Day </span><span class="Bold">1</span><span class="Bold"><br></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">41 - 59 mL/min<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">250 mg/m<span class="Sup">2</span><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16 - 40 mL/min<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">200 mg/m<span class="Sup">2</span><br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID209"></a>The data available for patients with severely impaired kidney function (creatinine clearance below 15 mL/min) are too limited to permit a recommendation for treatment. </p>
<p>These dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient’s tolerance based on the degree of bone marrow suppression.</p>
</div>
<div class="Section">
<a name="ID210"></a><a name="section-10.5"></a><p></p>
<h2>Formula Dosing</h2>
<p class="First"><a name="ID211"></a>Another approach for determining the initial dose of carboplatin is the use of mathematical formulae, which are based on a patient’s pre-existing renal function or renal function and desired platelet nadir. Renal excretion is the major route of elimination for carboplatin. (See <span class="Bold"><a href="#ID131">CLINICAL PHARMACOLOGY</a></span>). The use of dosing formulae, as compared to empirical dose calculation based on body surface area, allows compensation for patient variations in pretreatment renal function that might otherwise result in either underdosing (in patients with above average renal function) or overdosing (in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>).</p>
<p>A simple formula for calculating dosage, based upon a patient’s glomerular filtration rate (GFR in mL/min) and carboplatin target area under the concentration versus time curve (AUC in mg/mL•min), has been proposed by Calvert. In these studies, GFR was measured by <span class="Sup">51</span>Cr-EDTA clearance.</p>
<a name="ID212"></a><table width="100%">
<col width="100%">
<tbody class="Headless">
<tr class="First"><td class="Lrule Rrule Toprule" align="center" valign="top">
<span class="Underline">CALVERT </span><span class="Underline">FORMULA </span><span class="Underline">FOR </span><span class="Underline">CARBOPLATIN </span><span class="Underline">DOSING</span><span class="Underline"><br></span>
</td></tr>
<tr><td class="Lrule Rrule" align="center" valign="top">Total Dose (mg)=(target AUC) x (GFR + 25)<br>
</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Note</span><span class="Bold">: </span><span class="Bold">With </span><span class="Bold">the </span><span class="Bold">Calvert </span><span class="Bold">formula</span><span class="Bold">, </span><span class="Bold">the </span><span class="Bold">total </span><span class="Bold">dose </span><span class="Bold">of </span><span class="Bold">Carboplatin </span><span class="Bold">Injection </span><span class="Bold">is </span><span class="Bold">calculated </span><span class="Bold">in </span><span class="Bold">mg</span><span class="Bold">, </span><span class="Bold Underline">not </span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">m<span class="Sup">2</span></span><span class="Bold">.</span><span class="Bold"><br></span>
</td></tr>
</tbody>
</table>
<p><a name="ID213"></a>The target AUC of 4 mg/mL•min to 6 mg/mL•min using single-agent carboplatin appears to provide the most appropriate dose range in previously treated patients. This study also showed a trend between the AUC of single-agent carboplatin administered to previously treated patients and the likelihood of developing toxicity.</p>
<a name="ID214"></a><table width="100%">
<col width="27%">
<col width="41%">
<col width="32%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">% Actual Toxicity in Previously Treated Patients<br>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<br>AUC (mg/mL•min)<br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Gr 3 or Gr 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">Gr 3 or Gr 4 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4 to 5<br>6 to 7<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">16%<br>33%<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">13%<br>34%<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID215"></a><a name="section-10.6"></a><p></p>
<h2>Geriatric Dosing</h2>
<p class="First"><a name="ID216"></a>Because renal function is often decreased in elderly patients, formula dosing of carboplatin  based on estimates of GFR should be used in elderly patients to provide predictable plasma carboplatin AUCs and thereby minimize the risk of toxicity.</p>
</div>
<div class="Section">
<a name="ID217"></a><a name="section-10.7"></a><p></p>
<h2>PREPARATION OF INTRAVENOUS SOLUTIONS</h2>
<p class="First"><a name="ID218"></a>Carboplatin injection is a premixed aqueous solution of 10 mg/mL carboplatin. </p>
<p>Carboplatin aqueous solution can be further diluted to concentrations as low as 0.5 mg/mL with 5% Dextrose in Water (D<span class="Sub">5</span>W) or 0.9% Sodium Chloride Injection, USP.</p>
<p>When prepared as directed, carboplatin aqueous solutions are stable for 8 hours at room temperature (25° C). Since no antibacterial preservative is contained in the formulation, it is recommended that carboplatin aqueous solutions be discarded 8 hours after dilution.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID219"></a><a name="section-11"></a><p></p>
<p class="First"><a name="ID220"></a><span class="Bold">HOW SUPPLIED</span></p>
<p>Carboplatin injection</p>
<p><span class="Bold">NDC </span>67457-608-20 <span class="Bold">150 mg</span>/15 mL aqueous solution in multidose vials (with white flip-off seals), individually cartoned.  </p>
<div class="Section">
<a name="ID221"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First"><a name="ID222"></a>Unopened vials of carboplatin injection are stable to the date indicated on the package when stored at 20° - 25° C (68° to 77° F) [see USP Controlled Room Temperature]. Protect from light.</p>
<p>Carboplatin injection multidose vials maintain microbial, chemical, and physical stability for up to 14 days at 25° C following multiple needle entries.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Solutions for infusion should be discarded 8 hours after preparation.</p>
</div>
<div class="Section">
<a name="ID223"></a><a name="section-11.2"></a><p></p>
<h2>Handling and Disposal</h2>
<p class="First"><a name="ID224"></a>Caution should be exercised in handling and preparing carboplatin injection. Several guidelines on this subject have been published.<span class="Sup">1-4 </span></p>
<p>To minimize the risk of dermal exposure, always wear impervious gloves when handling vials containing carboplatin injection. If carboplatin injection contacts the skin, immediately wash the skin thoroughly with soap and water. If carboplatin injection contacts mucous membranes, the membranes should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> immediately and thoroughly with water. More information is available in the references listed below.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID225"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004- 165.</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling occupational exposure to hazardous drugs. OSHA, 1999. http://www.osha.gov/dts/ osta/otm/otm_vi/otm_vi_2.html</li>
<li>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. <span class="Italics">Am J Health-Syst Pharm. </span>2006;63:1172-1193.</li>
<li>Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society.</li>
</ol>
<p class="First"><a name="ID237"></a>Manufactured for:</p>
<p><span class="Bold">Mylan Institutional LLC</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:</p>
<p><span class="Bold">Agila Specialties Pvt. Ltd.</span></p>
<p>Bangalore, India</p>
<p>OCTOBER 2014 </p>
<p>NOVAPLUS is a registered trademark of Novation, LLC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID227"></a><a name="section-13"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><a name="ID228"></a><span class="Bold">Read this entire leaflet carefully. Keep it for future reference.</span></p>
<p><span class="Bold">Carboplatin Injection</span></p>
<p>This information will help you learn more about carboplatin injection. It cannot, however, cover all the possible warnings or side effects relating to carboplatin, and it does not list all of the benefits and risks of carboplatin. Your doctor should always be your first choice for detailed information about your medical condition and your treatment. Be sure to ask your doctor about any questions you may have.</p>
<p><span class="Bold">What is cancer?</span></p>
<p>Under normal conditions, the cells in your body divide and grow in an orderly, controlled fashion. Cell division and growth are necessary for the human body to perform its functions and to repair itself. Cancer cells are different from normal cells because they are not able to control their own growth. The reasons for this abnormal growth are not yet fully understood. </p>
<p>A tumor is a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of unhealthy cells that are dividing and growing fast and in an uncontrolled way. When a tumor invades surrounding healthy body tissue it is known as a <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumor</span>. A <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumor</span> can spread (metastasize) from its original location to other parts of the body.</p>
<p><span class="Bold">What is carboplatin?</span></p>
<p>Carboplatin is a medicine that is used to treat cancer of the ovaries. It acts by interfering with the division of rapidly multiplying cells, particularly cancer cells.</p>
<p><span class="Bold">Who should not take carboplatin?</span></p>
<p>Treatment with carboplatin is not recommended if you:</p>
<p><a name="ID229"></a>• are allergic to carboplatin or other platinum-containing products.</p>
<p>• have a weakened blood-forming system (<span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>) or significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>;</p>
<p>• are pregnant, intend to become pregnant, or are breast-feeding a baby.</p>
<p><span class="Bold">How is carboplatin used?</span></p>
<p>Only a professional experienced in the use of cancer drugs should give you this medication. Carboplatin is given by dripping the medicine slowly and directly into a vein (intravenous infusion) for 15 minutes or longer. Your doctor will determine the dose of carboplatin for you based on your weight, height, and kidney function. Carboplatin may be given alone or with other drugs. Treatment is usually repeated every four weeks for a number of cycles.</p>
<p>Before and after carboplatin treatment, your doctor may give you medication to lessen the <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> associated with this cancer treatment.</p>
<p><span class="Bold">What should you tell your doctor before starting treatment with carboplatin?</span></p>
<p>Discuss the benefits and risks of carboplatin with your doctor before beginning treatment.</p>
<p>Be sure to inform your doctor:</p>
<p><a name="ID230"></a>• If you are allergic to carboplatin or other platinum-containing products.</p>
<p>• If you are or intend to become pregnant, since carboplatin may harm the developing fetus. It is important to use effective birth control while you are being treated with carboplatin;</p>
<p>• If you are breast-feeding, since nursing infants may be exposed to carboplatin in this way;</p>
<p>• If you are taking other medicines, including all prescription and non -prescription (over-the-counter) drugs, since carboplatin may affect the action of other medicines; </p>
<p>• If you have any other medical problems, especially chicken pox (including recent exposure to adults or children with chicken pox), <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>, hearing problems, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or kidney disease, since treatment with carboplatin increases the risk and severity of these conditions.</p>
<p><span class="Bold">What should I avoid while taking carboplatin?</span></p>
<p>If you are pregnant or think you might be pregnant, or if you are breast feeding, let your doctor know right away. Carboplatin may harm your developing fetus or breast-feeding baby. If you are a woman of childbearing age, you should use birth control to avoid getting pregnant while you are taking carboplatin.</p>
<p>You should avoid contact with adults and children who have <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and tell your doctor right away if you show signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and/or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>. Also, while you are being treated with carboplatin or after you stop treatment, first check with your doctor before getting any immunizations (vaccinations). Avoid contact with adults or children who have received oral <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span> vaccine since they can pass the <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">polio</span> virus to you.</p>
<p><span class="Bold">What are the possible side effects of carboplatin?</span></p>
<p>Carboplatin may cause unwanted effects, particularly because carboplatin interferes with the growth of normal cells as well as cancer cells. For example, the occurrence of another cancer (secondary malignancy) has been reported in patients receiving cancer chemotherapy with multiple drugs. It is not always possible to tell whether such effects are caused by carboplatin, another drug you may be taking, or your illness. Because some of these effects may be serious, you will need close medical supervision during treatment with carboplatin.</p>
<p><span class="Italics">The most serious side effects of carboplatin are:</span></p>
<ul>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and reduced </span>blood cells, <span class="Bold">including reduced red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) and platelets (needed for proper blood clotting), </span>which may be severe enough to require blood transfusion. You should tell your doctor right away if you notice any unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including black <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span> or blood in the urine.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> - </span>carboplatin can temporarily lower the number of white blood cells in your blood, increasing the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>;</li>
<li>
<span class="Bold">life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> - </span>during and after treatment the doctor or nurse will observe you carefully for signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>;</li>
<li><span class="Bold">kidney and liver problems;</span></li>
<li><span class="Bold">loss of hearing or ringing in the ears;</span></li>
</ul>
<p><a name="ID232"></a><span class="Bold">Contact your doctor right away if you experience any of these effects, or notice effects that <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you or are troublesome.  </span></p>
<p><span class="Italics">Of the less serious side effects </span>associated with carboplatin treatment, the most common are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, burning, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the hands or feet.</p>
<p>This medicine was prescribed for your particular condition. It must be given under close medical supervision by a doctor trained in the use of drugs for the treatment of cancer.</p>
<p>This summary does not include everything there is to know about carboplatin. Medicines are sometimes prescribed for purposes other than those listed in patient leaflets. If you have questions or concerns, or want more information about carboplatin, your physician and pharmacist have the complete prescribing information upon which this information is based. You may want to read it and discuss it with your doctor. Remember, no written summary can replace careful discussion with your doctor.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </span></p>
<p>For more information, call Mylan Pharmaceuticals Inc. at 1-877-446- 3679 (1-877-4-INFO-RX). </p>
<p>Manufactured for:</p>
<p><span class="Bold">Mylan Institutional LLC</span></p>
<p>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:</p>
<p><span class="Bold">Agila Specialties Pvt. Ltd.</span></p>
<p>Bangalore, India</p>
<p>OCTOBER 2014 </p>
<p>NOVAPLUS is a registered trademark of Novation, LLC.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID238"></a><a name="section-14"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="15 mL - carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=806736d3-215a-4df5-8187-97f2161e5a53&amp;name=carbo-inj-novaplus-mylan-figure-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CARBOPLATIN 		
					</strong><br><span class="contentTableReg">carboplatin injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-608</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CARBOPLATIN</strong> (CARBOPLATIN) </td>
<td class="formItem">CARBOPLATIN</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-608-20</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091063</td>
<td class="formItem">11/09/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC 
							(790384502)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Onco Therapies Limited  (676159830)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Onco Therapies Limited </td>
<td class="formItem"></td>
<td class="formItem">676159830</td>
<td class="formItem">Analysis(67457-608), Manufacture(67457-608), Sterilize(67457-608), Label(67457-608), Pack(67457-608)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cea63fe8-1839-4bbf-a818-5a549abbf073</div>
<div>Set id: 806736d3-215a-4df5-8187-97f2161e5a53</div>
<div>Version: 1</div>
<div>Effective Time: 20141020</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC </div></p>
</body></html>
